Francesco Boin

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 58:1165-74. 2008
  2. pmc Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients
    Francesco Boin
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 60:2480-9. 2009
  3. ncbi request reprint Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis
    Francesco Boin
    Division of Rheumatology, The Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F Lord Bldg, Center Tower, Ste 4100, Baltimore, MD 21224, USA
    Ann N Y Acad Sci 1062:137-45. 2005
  4. pmc Scleroderma-like fibrosing disorders
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Suite 4100, Room 405, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 34:199-220; ix. 2008
  5. pmc Association of the autoimmune disease scleroderma with an immunologic response to cancer
    Christine G Joseph
    Ludwig Center, the Howard Hughes Medical Institutions, and the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Science 343:152-7. 2014
  6. doi request reprint Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature
    Allan C Gelber
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Medicine (Baltimore) 92:191-205. 2013
  7. pmc Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon
    Andrea Fava
    Division of Rheumatology, JohnsHopkins University School of Medicine, 5200 Eastern Avenue, Baltimore, MD 21224, USA
    Arthritis Care Res (Hoboken) 64:925-9. 2012
  8. pmc Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis
    Elizabeth N Le
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Rheum Dis 70:1104-7. 2011
  9. ncbi request reprint Autoimmunity in systemic sclerosis: current concepts
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Bldg Center Tower, Suite 4100, Room 412, Baltimore, MD 21224, USA
    Curr Rheumatol Rep 9:165-72. 2007
  10. pmc Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease
    Thomas Grader-Beck
    Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Rheum Dis 70:2218-24. 2011

Collaborators

Detail Information

Publications15

  1. pmc T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 58:1165-74. 2008
    ..The aim of this study was to investigate whether a polarized T cell phenotype in SSc is associated with lung disease or other clinical manifestations of SSc...
  2. pmc Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients
    Francesco Boin
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 60:2480-9. 2009
    ..This study was undertaken to investigate whether anti-beta2GPI and aCL are correlated with macrovascular disease, including ischemic digital loss and PAH, in SSc patients...
  3. ncbi request reprint Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis
    Francesco Boin
    Division of Rheumatology, The Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F Lord Bldg, Center Tower, Ste 4100, Baltimore, MD 21224, USA
    Ann N Y Acad Sci 1062:137-45. 2005
    ..94%). This small-volume ex vivo assay may prove to be a sensitive and specific tool to assess disease activity and to monitor response to therapy in patients with scleroderma...
  4. pmc Scleroderma-like fibrosing disorders
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Suite 4100, Room 405, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 34:199-220; ix. 2008
    ..Rheumatologists must be able to promptly recognize them to provide valuable prognostic information and appropriate treatment options for affected patients...
  5. pmc Association of the autoimmune disease scleroderma with an immunologic response to cancer
    Christine G Joseph
    Ludwig Center, the Howard Hughes Medical Institutions, and the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Science 343:152-7. 2014
    ..These results offer insight into the pathogenesis of scleroderma and provide support for the idea that acquired immunity helps to control naturally occurring cancers. ..
  6. doi request reprint Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature
    Allan C Gelber
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Medicine (Baltimore) 92:191-205. 2013
    ..Further, we provide a chronologic review of the literature regarding race, organ system involvement, and mortality in scleroderma; we furnish synopses of relevant reports, and summarize findings. ..
  7. pmc Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon
    Andrea Fava
    Division of Rheumatology, JohnsHopkins University School of Medicine, 5200 Eastern Avenue, Baltimore, MD 21224, USA
    Arthritis Care Res (Hoboken) 64:925-9. 2012
    ..This study evaluates the efficacy of fasudil, a RhoA/Rho kinase inhibitor, to reverse cold-induced vasospasm in patients with Raynaud's phenomenon (RP) secondary to systemic sclerosis (SSc; scleroderma)...
  8. pmc Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis
    Elizabeth N Le
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Rheum Dis 70:1104-7. 2011
    ..Immunosuppressive therapy may potentially alter the natural disease course of scleroderma. There have been reports of using mycophenolate mofetil (MMF) for the treatment of scleroderma skin disease...
  9. ncbi request reprint Autoimmunity in systemic sclerosis: current concepts
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Bldg Center Tower, Suite 4100, Room 412, Baltimore, MD 21224, USA
    Curr Rheumatol Rep 9:165-72. 2007
    ..Perturbed B-cell homeostasis has been reported in SSc. If confirmed in-vivo, these advances could lead to new disease-modifying therapeutic strategies directed at SSc-specific immune effector pathways...
  10. pmc Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease
    Thomas Grader-Beck
    Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Rheum Dis 70:2218-24. 2011
    ..Whether patients with SSc develop antibodies to carbohydrates is not known...
  11. ncbi request reprint The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis
    Tricia R Cottrell
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Rheum Dis 73:1060-6. 2014
    ..To determine whether the pattern of skin involvement can predict clinical features, risk of restrictive lung disease (RLD) and survival in a large scleroderma (SSc) cohort...
  12. pmc Immunotherapy of systemic sclerosis
    Rebecca Manno
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA
    Immunotherapy 2:863-78. 2010
    ..Clinical efficacy and safety of antifibrotic treatments (e.g., imatinib) await confirmation. Newer biological agents targeting key molecular or cellular effectors in scleroderma pathogenesis are now available for clinical testing...
  13. doi request reprint Resolution of pansclerotic morphea after treatment with antithymocyte globulin
    Philip Song
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Nat Rev Rheumatol 5:513-6. 2009
    ..He also reported difficulties with swallowing and a 20 kg weight loss...
  14. ncbi request reprint Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor
    Michael Maes
    IRCCS, Istituto, Fatebenefratelli, Brescia
    Schizophr Res 54:281-91. 2002
    ....
  15. ncbi request reprint Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia
    Luisella Bocchio Chiavetto
    Genetic Unit, IRCCS S Giovanni di Dio, Fatebenefratelli, Breschia, Italy
    Biol Psychiatry 51:480-4. 2002
    ..Three functional haplotypes of the gene (GCC, ACC, ATA) have been described, derived from different combinations of three "single nucleotide polymorphisms" and directly related to the expression levels of the protein...